Replies to post #583921 on NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Excellent Danish Dude!

Here is a “hard working” Committee:

EANO ANNUAL REPORT 2021

PUBLICATION ACTIVITY COMMITTEE

The Publishing Activity Committee (Wolfgang Wick, DE (Chair), Martin Taphoorn, NL (co-chair), Linda Dirven, NL, Francois Ducray, FR, Norbert Galldiks, DE, Monika Hegi, CH, Martin Klein, DE, Katrin Lamszus, DE, Simone Niclou, LU, Matthias Preusser, AT, Patrick Roth, CH, Roberta Rudà, IT, Felix Sahm, DE, Susan Short, UK, Riccardo Soffietti, IT, Martin Van den Bent, NL, Michael Weller, CH, Pieter Wesseling, NL) consists of editors that represent EANO in the following journals: Neuro-Oncology, Neuro-Oncology Practice and Neuro-Oncology Advances. The main tasks of the committee are to ensure scientific representation of EANO in the journals, providing a link between EANO and the journal publisher and promoting the publication activities within the EANO membership.

https://www.eano.eu/fileadmin/user_upload/0078_EANO_Annual_Report_2021.pdf

Wolfgang Wick : First results on the DCVax phase III trial: raising more questions than providing answers . https://pubmed.ncbi.nlm.nih.gov/30137551/

Matthias Preusser : Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana? https://academic.oup.com/neuro-oncology/article/25/4/631/6958519?login=false

Susan Short : one of the co-signees of the JAMA “Comment”.
Comment
November 30, 2022
The need to report as-planned analyses and the weakness of historical controls
Dr. Matt Williams, London
Dr. Paul Sanghera, Birmingham
Prof. Susan Short, Leeds
Dr. Anup Vinayan, London
Dr. Juliet Brock, Oxford
Dr. Chris Herbert, Bristol
Dr. Joanne Lewis, Newcastle
Dr. Shaveta Mehta, Liverpool
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

Patrick Roth : Vaccination ( negative phase 3 trials: ACT-IV, DCVax-L) https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167233202

Martin J van den Bent :
First results on the DCVax phase III trial: raising more questions than providing answers.https://pubmed.ncbi.nlm.nih.gov/30137551/

Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana? https://academic.oup.com/neuro-oncology/article/25/4/631/6958519?login=false

Michael Weller - 2016 - Min 10.30

[dstock07734]

Dude,

Magnificent post that should be stickied!

[iclight]

Every doctor who "signed" the Jama paper had a conflict of interest. Most were barely involved in the trial but were probably at the hospital where the trial happened and might have taken a patients blood so they wanted a publication credit. The majority of sites saw zero improvement based on simple math in their miniscule number of patients in the trial despite the cherry picking. The majority of sites in the trial had less than 5 patients. Many had one or two.

Patient level data, which they have for the P3 but won't release, would show this. Patient level data is also what LL said would be need to show efficacy, and the don't have that for the ECA.

Trying to discredit ACTUAL oncologists who disagree with this farce of a trial is character assassination pure and simple. It's all longs have since they actually paid Stupp for consultation and he said the data sucked, just like any doctor not shilling for the company by getting their little mention on the bullshit data paper.